drugset / Trial / NCT06546436
The Safety and Efficiency of a Single Dose of CARC-101C in Patients With Autoimmune Type 1 Diabetes Mellitus
Phase 0
Not yet recruiting
12 enrolled
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Carcell Biopharma Ltd. · collab
Non-randomizedSequentialOpen-labelPrevention
Summary
This study investigated the safety, efficiency, pharmacokinetics and pharmacokinetics of CARC-101C in patients with autoimmune type 1 diabetes. A single dose, dose escalation, open study design was used.
Timeline
- Start
- 2024-08-15
- Primary completion
- 2025-11-15
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CARC-101C | Cell therapy | 3e+10 cells | Other |
| Comparator | CARC-101C | Cell therapy | 3e+11 cells | Other |